Gluck N, Schwob O, Krimsky M, Yedgar S. Activation of cytosolic phospholipase A2 and fatty acid transacylase is essential but not sufficient for thrombin-induced smooth muscle cell proliferation. Am J Physiol Cell Physiol 294: C1597-C1603, 2008. First published April 2, 2008 doi:10.1152/ajpcell.00206.2007.-Thrombin is a potent stimulant of smooth muscle cell (SMC) proliferation in inflammatory conditions, leading to pathological thickening of vascular walls in atherosclerosis and airway remodeling in asthma. Cell proliferation requires the formation and remodeling of cell membrane phospholipids (PLs), involving the activation of PL-metabolizing enzymes. Yet, the role of specific PL-metabolizing enzymes in SMC proliferation has hardly been studied. To bridge this gap, in the present study, we investigated the role of key enzymes involved in PL metabolism, the PL-hydrolyzing enzyme phospholipase A2 (PLA2) and the PL-synthesizing enzyme lysophosphatidic acid-fatty acid transacylase (LPAAT), in thrombin-induced proliferation of bovine aortic SMCs (BASMCs). Concomitantly with the induction of BASMC proliferation, thrombin activated cytosolic PLA2 (cPLA2-␣), expressed by selective release of arachidonic acid and mRNA expression, as well as LPAAT, expressed by nonselective incorporation of fatty acid and mRNA expression. Specific inhibitors of these enzymes, arachidonyl-trifluoromethyl-ketone for cPLA2 and thimerosal for LPAAT, suppressed their activities, concomitantly with suppression of BASMC proliferation, suggesting a mandatory requirement for cPLA2 and LPAAT activation in thrombin-induced SMC proliferation. Thrombin acts through the protease-activated receptor (PAR-1), and, accordingly, we found that thrombin-induced BASMC proliferation was suppressed by the PAR-1 inhibitor SCH-79797. However, the PAR-1 inhibitor did not prevent thrombin-induced mRNA expression of cPLA2 and LPAAT, implying that the activation of cPLA2 and LPAAT is essential but not sufficient for thrombin-induced proliferation of BASMCs. lysophosphatidic acid acyltransferase; protease-activated receptor-1
transacylase (LPAAT), to form new PLs required for membrane remodeling and cell growth. This process thus assigns a pivotal role to PL-metabolizing enzymes in cell proliferation. Nonetheless, scant research has been devoted to the role of PL metabolism in thrombin-induced SMC proliferation (27) .
The PLA 2 family consists of secretory (sPLA 2 ) and intracellular enzymes, which include cytosolic PLA 2 (cPLA 2 ) and Ca 2ϩ -independent PLA 2 (iPLA 2 ) (11). iPLA 2 is generally considered a housekeeping enzyme, maintaining the membrane PL composition, whereas the other PLA 2 s have been reported to be activated in inflammatory conditions. While iPLA 2 and sPLA 2 have no preference for specific fatty acyl chains, cPLA 2 is specific to arachidonic acid (AA)-carrying PLs and is thus considered a major contributor of AA for the production of inflammatory eicosanoids.
Enhanced activities of both thrombin and PLA 2 are characteristic of inflammatory conditions. Yet, the role of PLA 2 isoenzymes in thrombin-induced SMC proliferation has been little studied, despite the key role of PLA 2 in membrane PL metabolism. A previous study reported that cPLA 2 -mediated AA release is critical for the growth of human vascular SMCs in medium supplemented with growth factors (other then thrombin). However, only a single study (27) has directly addressed PLA 2 involvement in thrombin-induced SMC growth, suggesting the requirement of iPLA 2 in thrombin-induced proliferation of rat vascular SMCs, whereas the other PLA 2 s have not been studied this context.
At the reverse pathway of membrane PL metabolism, FA transacylation into lysophospholipid has been reported to be involved in cancer cell survival and growth, and its inhibition induced their apoptosis (17) , but its role in SMC proliferation has not been studied.
The present study was undertaken to elucidate the role of PL metabolic enzymatic activities, specifically those involved in FA release and reacylation, during thrombin-induced SMC proliferation using bovine aortic SMCs (BASMCs). We report that the activation of cPLA 2 , releasing AA, and of LPAAT, which incorporates different FA types into membrane PLs, is required but not sufficient for thrombin-induced BASMC proliferation.
MATERIALS AND METHODS
Materials. Culture medium, FCS, antibiotics, and trypsin (solution A) were purchased from Bet Haemek Biological Industries. [ 3 H]thymidine, AA, and oleic acid (OA) were purchased from Amersham (Aylesbury, UK). Human thrombin was purchased from OMRIX Biopharmaceuticals (Brussels, Belgium). The protease-activated receptor (PAR)-1 inhibitor N 3 -cyclopropyl-7-{[4-(1-methylethyl)phenyl]methyl}-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine dihydrochloride (SCH-79797) was purchased from Tocris Bioscience. BSA (essentially FA free), trypan blue solution, bromoenolactone (BEL; iPLA 2 inhibitor), arachidonyl-trifluoromethyl-ketone (AACOCF3; cPLA 2 inhibitor), and all other buffers and chemicals were purchased from Sigma (St. Louis, MO).
Cell cultures. SMCs harvested from the bovine aorta (BASMCs) were generously provided by the laboratory of I. Vlodawsky (Hadassah University Hospital, Jerusalem, Israel). Cells were grown at 5% CO 2 at 37°C in DMEM (4.5% glucose) with 10% FCS, glutamine, penicillin, and streptomycin. Medium was changed every 3-4 days. Experiments were conducted using cells from generations 4 -12. To synchronize the cell cycle, cells were subjected to starvation by an incubation with 0.2% FCS for 48 h.
Cell viability was determined by vital staining using 0.1% trypan blue.
Determination of BASMC proliferation. The cell growth capacity was determined by the conventional method of incorporation of radioactively labeled thymidine into DNA (14) . Confluent cells were synchronized by "starvation" as described above and incubated under the different treatments for the desired times, and [
3 H]thymidine (2 Ci/well in 96-well plates) was added to the culture medium for 2 h. Cells were then washed with PBS, incubated in 10% trichloroacetic acid (TCA) at 4°C for 1 h, washed twice with 5% TCA, and incubated for 1 h in 0.2 N NaOH at 37°C. The fluid was collected, and its radioactivity was measured in a scintillation counter.
Determination of PLA2 activity by the release of AA and OA. cPLA2 is specific to AA-carrying PLs, whereas sPLA2 and iPLA2 have no preference for FAs and can release both AA and OA. Therefore, monitoring of the production of AA and OA by cells is conventionally used for the differentiation of cPLA2 from sPLA2 and iPLA2 activities. mRNA expression of cPLA2 and LPAAT by RT-PCR. Cells were grown to confluence in six-well plates and synchronized as described above. On the day of the experiment, cells were incubated with thrombin-supplemented or -deficient (control) fresh medium (with 0.2% serum) for 1, 4, or 12 h at 37°C. Cells were then washed in PBS and lysed with 0.5 ml TriReagent (T-9424, Sigma). RNA was isolated according to the manufacturer's instructions, and the RNA concentration and purity were determined by spectrophotometry. RNA was reverse transcribed into cDNA with Moloney murine leukemia virus reverse transcriptase (M1701, Promega). RNA (5 g) was mixed with RT buffer containing 50 mM Tris (pH 8.3), 75 mmol/l KCl, 3 mmol/l MgCl2, and 10 mmol/l DTT, 200 units reverse transcriptase, 40 units RNAsin, 0.2 g oligo dT, and 1 mmol/l dNTP, for a total volume of 20 l. Samples were incubated for 2 h at 37°C followed by 5 min at 95°C, supplemented with 80 l of PCR water, and stored at Ϫ20°C until subjected to PCR amplification. For cPLA2, PCR was performed using bovine-compatible human cPLA2-␣ primers (sense: 5Ј-TGTTCAACAGAGTTTTGG-3Ј and antisense: 5Ј-AACAGAGCAACGAGATGG-3Ј) to amplify a 900-bp fragment (15) . cDNA (2.5 l) was mixed with ReddyMix PCR MasterMix (1.5 mmol/l MgCl 2) (ABgene) for a total volume of 25 l. PCRs were carried out in a PT-100 (MJ Research, Watertown, MA) programmable thermal controller with an initial 5-min denaturation at 94°C followed by the cycled program of 30 s at 94°C (denaturation), 30 s at 50°C (annealing), and 2 min at 72°C (extension). PCRs were carried out for 32 cycles, and a final extension of 10 min at 72°C ended the reaction. PCR products (20 l) were analyzed by 1.5% agarose gel electrophoresis and visualized with ethidium bromide.
For LPAAT, PCR was performed using primers (sense: 5Ј-CTGT-GTGTGCGTGCGAGGAC-3Ј and antisense: 5Ј-CAGCATGGCGC-CGTTGTGGTT-3Ј) to amplify a 402-bp fragment (16) . PCRs were carried out with an initial 5-min denaturation at 94°C followed by the cycled program of 30 s at 94°C (denaturation), 30 s at 62°C (annealing), and 30 s at 72°C (extension). PCRs were carried out for 26 cycles, and a final extension of 10 min at 72°C ended the reaction. Results were normalized to 28S rRNA.
cPLA 2 phosphorylation by Western blot analysis. Cells were grown to confluence in six-well plates and synchronized in medium with 0.2% serum for 24 h. On the day of the experiment, cells were stimulated with thrombin (10 U/well) for 1 h. Cells, on ice, were washed twice with 1.5 ml cold PBS, and 150 l of lysis buffer [20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM ␤-glycerophosphate, 1 mM sodium orthovanadate, 1 mM PMSF, and 1 g/ml leupeptin] were added for 5 min. Cells were scraped, transferred to microcentrifuge tubes, and sonicated four times for 5 s on ice. Insoluble cellular components were removed by centrifugation at 10,000 rpm for 10 min at 4°C. The protein content of the supernatant was determined according to the Bradford method using BSA as the standard. Extracts (40 g protein) were mixed with 4ϫ loading buffer [125 mM Tris (pH 6.8), 20% glycerol, 10% mercaptoethanol, 4.6% SDS, and 0.02% bromophenol blue] and boiled for 5 min. Proteins were separated by 10% Tris-glycine SDS-PAGE and transferred onto nitrocellulose membranes (Protran BA85, Schleicher & Schuell Bioscience) at 150 mA for 2 h. For cPLA 2 (no. 2832, Cell Signaling) and phospho-cPLA2 (no. 2831, Cell Signaling), membranes were blocked for 1 h in Tris-buffered saline-0.1% Tween 20 (TBST) containing 5% nonfat milk powder, washed three times for 5 min in TBST, and incubated with 1:1,000 diluted antibodies overnight at 4°C in TBST containing 5% BSA. Membranes were washed three times for 5 min in TBST, incubated with a 1:7,500 dilution of goat anti-rabbit secondary antibody (no. 111-035-144, Jackson ImmunoResearch) conjugated to horseradish peroxidase for 1 h, and washed three times for 5 min in TBST before detection using SuperSignal Chemiluminescent substrate (Pierce, Rockford, IL).
Statistical analysis. Data were examined for statistical significance using SPSS 8.02 software for Student's t-test, and differences were considered significant at P Ͻ 0.05.
RESULTS

Thrombin-induced proliferation of BASMCs.
To assess the induction of SMC proliferation by thrombin and calibrate its effect, we determined thymidine incorporation into confluent SMCs under increasing concentrations of thrombin and compared it with SMC proliferation in serum-containing (10%) medium. As shown in Fig. 1 , thrombin enhanced SMC proliferation in a concentration-dependent manner, reaching FCSinduced growth at 2 U/ml, which is conventionally used in other studies (8) . However, the proliferation-inducing activity differed significantly between thrombin batches, and, therefore, every new batch was calibrated independently against FCS, and the thrombin concentration used in the following experiments was at least 2 U/ml.
Determination of endogenous PLA 2 activity in response to thrombin. As noted in the Introduction, cPLA 2 is specific to AA-carrying PLs, whereas sPLA 2 and iPLA 2 have no preference for a fatty acyl chain. Therefore, to test the possible activation of endogenous PLA 2 s by thrombin, cell membrane PLs were prelabeled with either radioactive AA ([ 3 H]AA) or OA ([ 3 H]OA), as described in MATERIALS AND METHODS, and cellular PLA 2 activities were determined by the release of free AA or OA following treatment with thrombin for increasing time periods (up to 2 h). As shown in Fig. 2 , it was found that thrombin enhanced the release of AA but had no effect on OA release. However, in the process of membrane formation/ remodeling, the released FA might be rapidly reacylated and thus not accumulate in the extracellular medium and escape detection. To examine this possibility, the experiment was repeated in the presence of the reacylation inhibitor thimerosal (19, 28) . The results shown in Fig. 2 demonstrate that the reacylation inhibitor indeed elevated the level of AA accumulation in the extracellular medium in a concentration-dependent manner but did not affect the OA level. It thus appears that thrombin activates cPLA 2 but not the other two PLA 2 types.
Effect of cPLA 2 -and iPLA 2 -specific inhibitors on SMC proliferation. As noted in the Introduction, a previous study (27) reported the requirement of iPLA 2 activity in thrombininduced proliferation of rat vascular SMCs, whereas the results described above (Fig. 2) suggest the involvement of cPLA 2 , but not of iPLA 2 or sPLA 2 , in thrombin-induced BASMC proliferation. To further examine this conclusion, we determined the effect of the specific inhibitor of cPLA 2 (AACOCF 3 ) and of iPLA 2 (BEL) on BASMC proliferation under thrombin stimulation. The results shown in Fig. 3A demonstrate that the cPLA 2 inhibitor suppressed thrombin-induced cPLA 2 activity, as measured by AA release. As an inhibitor that binds to the enzyme protein, AACOCF 3 is expected to inhibit (depending on concentration) the basal activity as well (as shown in Fig.  3 ). Yet, the inhibitor effect under thrombin activation is more profound, thus showing that it inhibited the stimulated activity as well. The results shown in Fig. 3B demonstrate that the cPLA 2 inhibitor concomitantly suppressed BASMC proliferation, thereby supporting the conclusion that cPLA 2 activation is required for thrombin-induced BASMC proliferation.
Conversely, no effect of the iPLA 2 inhibitor was observed on AA release (not shown). To further test whether iPLA 2 activation is not required in this process, the BEL effect on cell proliferation was examined using two methods: cell counting and thymidine incorporation, as described in MATERIALS AND METHODS. In repeated experiments, no inhibition of thrombininduced proliferation by BEL was observed, as shown in Fig.  3B . These results support the conclusion that iPLA 2 does not play a significant role in this BASMC proliferation.
Thrombin-induced cPLA 2 mRNA expression. After the above experiments, which suggested the requirement of cPLA 2 activation for thrombin-induced BASMC proliferation, cPLA 2 mRNA expression was determined after the induction of proliferation by thrombin. As shown in Fig. 4A , consistent with an increase in enzymatic activity (Figs. 2 and 3) , thrombin elevated cPLA 2 mRNA expression up to 2.5-fold.
Thrombin-induced cPLA 2 activation was further demonstrated by the results shown in Fig. 4B , which show that concomitant with the enhanced lipolytic activity, thrombin also induced cPLA 2 phosphorylation, which is required for enzyme activation (12, 13) .
Activation of FA incorporation into membrane PLs of thrombin-induced proliferating BASMCs. As discussed in the Introduction, cell growth obviously requires increased membrane production, and if this involves AA release from PL by PLA 2 , as described above, then FA reacylation into lysophospholipids would follow. To examine the requirement for transacylase activity in thrombin-induced BASMC growth, we determined the thrombin effect on AA and OA incorporation into cell membranes. As shown in Fig. 5A , thrombin enhanced OA incorporation into cell membrane PLs. However, whereas thrombin elevated the release of AA (Fig. 2) , it did not increase the net AA incorporation into cell PLs (not shown). These findings suggest that during cell proliferation thrombin exerts membrane PL remodeling by increasing the level of PLcontaining OA (and possibly other non-AA FAs) while releasing AA.
Thrombin-induced LPAAT expression. Subsequent to the thrombin-induced FA incorporation, we determined the thrombin effect on LPAAT mRNA expression. As shown in Fig. 5B , LPAAT mRNA expression was clearly enhanced by treatment of BASMCs with thrombin. The role of LPAAT is further documented by Fig. 6 , showing that thimerosal, the LPAAT inhibitor, also suppressed BASMC proliferation, demonstrating the requirement for FA transacylation in thrombin-induced BASMC growth. 2 and LPAAT. Thrombin action on SMCs has been reported to be mediated by the PAR family, which includes four isoforms: PAR-1, PAR-2, PAR-3, and PAR-4 (24). It is generally accepted that PAR-1 is present in SMCs and takes part in thrombin-induced proliferation, whereas the presence of other PARs in SMCs and their roles in proliferation are not unequivocally clear. It is likely that this differs between different aortic and venous SMCs (3, 6, 7) . Accordingly, in the present study, we determined the effect of the PAR-1 inhibitor SCH-79797 (1) on thrombin-induced BASMC proliferation as well as its effect on the activation of Fig. 4 . Induction of mRNA expression (A) and phosphorylation (B) of cPLA2 by thrombin. A: confluent/synchronized cells were incubated for the indicated times in either control or thrombin-supplemented medium, and enzyme mRNA expressions were determined by RT-PCR. Each data point is the mean Ϯ SE for 3 replicates. *P ϭ 0.003. B: cells were incubated for 1 h with or without thrombin, lysed, and then subjected to Western blot analysis using antibodies to cPLA2 or its phosphorylated form (cPLA2-P) as described in MATERIALS AND METHODS. The Shown are representative blots of 3 reproducible experiments in which treatment with thrombin increased cPLA2-P by 757%, 427%, and 149%, as determined by densitometry. . B: confluent/synchronized cells were incubated for 30 min with or without the cPLA2 inhibitor (AACOCF3) or the iPLA2 inhibitor [bromoenolactone (BEL)] and then incubated overnight in either control or thrombin-supplemented medium, and [ 3 H]thymidine incorporation was measured during the following 2 h. Cells were washed and then lysed for the determination of the cellular label content. Each data point is the mean Ϯ SE for 5 replicates. *P ϭ 0.04; **P ϭ 0.001. cPLA 2 and LPAAT. As shown in Fig. 7 , the PAR-1 inhibitor clearly suppressed thrombin-induced BASMC proliferation. However, to our surprise, in three reproducible experiments, we found that the PAR-1 inhibitor did not affect either cPLA 2 or LPAAT enzymatic activity. For example, [ To further support this surprising finding, we examined the SCH-79797 effect on mRNA expression of PL-metabolizing enzymes. As shown in Fig. 8 , the PAR-1 inhibitor did not affect thrombininduced cPLA 2 or LPAAT mRNA expression, thereby suggesting a dual mechanism for thrombin action in the induction of BASMC proliferation, as discussed below. 3 H]OA content was determined. Each data point is the mean Ϯ SE for 4 replicates. *P Ͻ 0.05; **P Ͻ 0.02. B: confluent/synchronized cells were incubated for the indicated times in either control or thrombinsupplemented medium, and enzyme mRNA expressions were determined by RT-PCR. Each data point is the mean Ϯ SE for 3 replicates. *P ϭ 0.002. 
Effect of PAR-1 inhibition on thrombin-induced BASMC proliferation and activation cPLA
DISCUSSION
SMC proliferation is a key process in pathological thickening of the vascular wall in the development of atherosclerosis and stenosis and in airway remodeling in asthma. Both processes are facilitated by inflammatory conditions. Cell growth involves the formation of new cell membrane components, PLs in particular. The formation of membrane PLs can be done by de novo synthesis and/or PL remodeling involving lipolysis and reconstitution. Both thrombin and products of PL hydrolysis are markedly enhanced in inflammatory conditions. Products of PL hydrolysis, commonly denoted inflammatory lipid mediators, such as lysophospholipid, lysophosphatidic acid in particular, as well as AA and its eicosanoid derivatives, induce SMC proliferation, leading to related pathology (2, 9, 10, 13, 18) . PL lipolysis and the subsequent production of inflammatory lipid mediators can occur by multiple enzymatic pathways (20) , but PLA 2 enzymes play a major role in these processes. In addition, extracellular sPLA 2 s, which are secreted by activated inflammatory cells, can act as receptor ligands, independent of their lipolytic activity, to activate cell signaling and subsequent cell proliferation (25) . Yet, the possible involvement of PL-metabolizing enzymes in thrombin-induced SMC proliferation has not been well investigated, as discussed in the Introduction.
The present study shows that the thrombin-induced proliferation of BASMCs requires 1) the activation of lipolytic enzyme cPLA 2 (but not iPLA 2 or sPLA 2 ), as shown by its elevated mRNA expression and enzyme phosphorylation, selective AA release, and the concomitant inhibition of cell proliferation by the selective cPLA 2 inhibitor AACOCF 3 ; and 2) the activation of the FA-acylating enzyme LPAAT, as shown by its elevated mRNA expression, incorporation of FAs, and the concomitant inhibition of cell proliferation by the acylation inhibitor thimerosal.
Previous studies have demonstrated the involvement of iPLA 2 (also called Ca 2ϩ -independent cPLA 2 -␥) in membrane remodeling (4) and FA transacylation (26) . It was also reported that thrombin-stimulated activation of MAPKs in rabbit ventricular myocytes is dependent on iPLA 2 activity (5). Of particular relevance to the present study is the report of Yellaturu and Rao (27) , which showed that thrombin-induced proliferation of rat thoracic aorta SMCs required increased activity of iPLA 2 , and this was inhibited by BEL (at 10 M). In variance to that, in the present study, we could not verify the involvement of iPLA 2 in thrombin-induced proliferation of BASMCs, since, except for AA, no release of other FA could be detected, even in the presence of the transacylation inhibitor (which further increased AA release). In addition, application of the same procedure of Yellaturu and Rao, namely, treatment with the iPLA 2 inhibitor BEL (up to 50 M in some experiments), did not affect the thrombin-induced AA release. Although we do not have a satisfactory explanation for the discrepancy between our findings and those of Yellaturu and Rao, this might be due to differences in species (rats vs. cows), or methodology, e.g., inhibition of FA reacylation, as applied in the present study. Also, a later study (21) , using HEK-293 cells and Caki-1 cells, showed that iPLA 2 -␤ and iPLA 2 -␥ may differ in their effect on cell growth and can be selectively inhibited by R-and S-enantiomers of BEL. This might suggest that the distinction between iPLA 2 isoforms and their selective inhibition (by BEL enantiomers) should be considered when studying the role of iPLA 2 in cell function.
On the other hand, we clearly found that thrombin-induced BASMC proliferation is associated with cPLA 2 expression and selectively enhanced AA release. Both AA release and cell proliferation were suppressed by the cPLA 2 inhibitor AACOCF 3 . These findings strongly suggest that cPLA 2 activation is required for thrombin-induced BASMC proliferation. This conclusion is in accord with the report of Anderson and Marshall (2) , which showed that the cPLA 2 -mediated (AACOCF 3 -inhibited) release of AA is critical for the proliferation of human artery vascular SMCs (although in growth medium, not thrombin-supplemented medium).
At the pathway of PL formation, the present study also showed that thrombin-induced BASMC proliferation requires the activation of FA transacylase, as shown by the enhanced FA incorporation and expression of LPAAT mRNA, and inhibition of all of the above by the acylation inhibitor. As noted above, both PL hydrolysis and reconstitution may occur by more than one enzymatic pathway. The present study shows that in thrombin-induced BASMC proliferation, membrane PL formation involves their hydrolysis by cPLA 2 and FA incorporation by LPAAT.
Taken together, these findings suggest that by activation of AA-specific cPLA 2 and non-FA-specific LPAAT, thrombininduced BASMC proliferation is associated with the increased production of AA, a precursor for diverse proinflammatory eicosanoids. Since elevated thrombin levels and subsequent SMC proliferation are characteristic of inflammatory conditions, it is probable that the thrombin-induced AA and subsequent eicosanoid production are important mechanisms by which thrombin exerts its proinflammatory effect.
Of particular interest in this study is the finding that the PAR-1 inhibitor suppressed thrombin-induced cell proliferation without affecting the thrombin-induced activity of the above PL-metabolizing enzymes (Figs. 7 and 8 ). Yet, both cPLA 2 and LPAAT inhibitors independently suppressed thrombin-induced BASMC proliferation (Figs. 3 and 6 ). Taken together, these findings appear to suggest that thrombin induces SMC proliferation by two inde- Fig. 8 . PAR-1 inhibitor does not affect mRNA expression of cPLA2 and LPAAT. Confluent/synchronized cells were incubated with the PAR-1 inhibitor SCH-79797 for 30 min prior to treatment with thrombin for 12 h. mRNA levels of the enzymes were determined as described in MATERIALS AND METHODS. Each data point is the mean Ϯ SE for 2 replicates. No significant differences were observed between the bars denoted with * or **. pendent mechanisms: 1) via its proteolytic action on PAR-1 and 2) via PAR-1-independent activation of PL-metabolizing enzymes cPLA 2 and LPAAT. It is possible, of course, that the thrombin-induced activation of PL-metabolizing enzymes is mediated by other PARs or another mechanism(s) altogether, which is yet to be explored. Nevertheless, the results shown in Figs. 3B, 6, and 7 demonstrate that each of the inhibitors tested, namely, the cPLA 2 inhibitor (Fig. 3B) , the LPAAT inhibitor (Fig. 6) , and PAR-1 inhibitor (Fig. 7) , abolished thrombin-induced BASMC proliferation, bringing it to that of control, thrombin-untreated cells. This implies that the effects of the two mechanisms are not additive. Instead, both are essential since blockade of either of them eliminates the induction of BASMC proliferation by thrombin.
The PAR-mediated mechanism has been given considerable attention, whereas the other mechanism has hardly been studied, and its extensive investigation is clearly of interest. The findings of the present study thus open a new avenue in the study of thrombin function and might introduce new insights into the control of thrombin-associated pathological conditions by the regulation of cPLA 2 and/or LPAAT.
